Structure-activity relationship study of N 6-(2-(4-(1 H -Indol-5-yl)piperazin-1-yl)ethyl)- N 6-propyl-4,5,6,7- tetrahydrobenzo[ d ]thiazole-2,6-diamine analogues: Development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5826-5840

  Johnson, Mark ^a   Antonio, Tamara ^b   Reith, Maarten E A ^b   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOXONIUM CHLORIDE; DIAMINE DERIVATIVE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N6 [2 [4 (1H INDOL 5 YL)PIPERAZIN 1 YL]ETHYL] N6 PROPYL 4,5,6,7 TETRAHYDROBENZO[D]THIAZOLE 2,6 DIAMINE DERIVATIVE; ROPINIROLE; SPIPERONE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; NONHUMAN; PARKINSON DISEASE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; FEMALE; FREE RADICAL SCAVENGERS; HEK293 CELLS; HUMANS; INDOLES; LOCOMOTION; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RESERPINE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THIAZOLES;

EID: 84863096828     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300268s     Document Type: Article

References (44)

1. Kebabian, J. W.; Calne, D. B. Multiple receptors for dopamine Nature 1979, 277, 93-96
2. Giros, B.; Martres, M. P.; Sokoloff, P.; Schwartz, J. C. Gene cloning of human dopaminergic D3 receptor and identification of its chromosome C. R. Acad. Sci., Ser. III 1990, 311, 501-508
3. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 1990, 347, 146-151
4. Van Tol, H. H.; Bunzow, J. R.; Guan, H. C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine Nature 1991, 350, 610-614
5. Sunahara, R. K.; Guan, H. C.; O'Dowd, B. F.; Seeman, P.; Laurier, L. G.; Ng, G.; George, S. R.; Torchia, J.; Van Tol, H. H.; Niznik, H. B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 Nature 1991, 350, 614-619
6. Strange, P. G. New insights into dopamine receptors in the central nervous system Neurochem. Int. 1993, 22, 223-236
7. Civelli, O.; Bunzow, J. R.; Grandy, D. K. Molecular diversity of the dopamine receptors Annu. Rev. Pharmacol. Toxicol. 1993, 33, 281-307
8. Gurevich, E. V.; Joyce, J. N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons Neuropsychopharmacology 1999, 20, 60-80
9. Emilien, G.; Maloteaux, J. M.; Geurts, M.; Hoogenberg, K.; Cragg, S. Dopamine receptors: physiological understanding to therapeutic intervention potential Pharmacol. Ther. 1999, 84, 133-156
10. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects Pharmacol. Ther. 2006, 112, 281-333
11. Park, B. H.; Fishburn, C. S.; Carmon, S.; Accili, D.; Fuchs, S. Structural organization of the murine D3 dopamine receptor gene J. Neurochem. 1995, 64, 482-486
12. Paulus, W.; Jellinger, K. The neuropathologic basis of different clinical subgroups of Parkinson's disease J. Neuropathol. Exp. Neurol. 1991, 50, 743-755
13. Sherer, T. B.; Betarbet, R.; Greenamyre, J. T. Pathogenesis of Parkinson's disease Curr. Opin. Invest. Drugs 2001, 2, 657-662
14. Wooten, G. F. Movement Disorders. Neurologic Principles and Practice; McGraw-Hill: New York, NY, 1997; pp p153-160.
15. Jenner, P. Oxidative stress in Parkinson's disease Ann. Neurol. 2003, 53 (Suppl. 3) S26-S36; discussion S36-S88
16. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease Science 2003, 302, 819-822
17. Betarbet, R.; Sherer, T. B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A. V.; Greenamyre, J. T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 2000, 3, 1301-1306
18. Bindoli, A.; Rigobello, M. P.; Deeble, D. J. Biochemical and toxicological properties of the oxidation products of catecholamines Free Radical Biol. Med. 1992, 13, 391-405
19. Marsden, C. D.; Parkes, J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy Lancet 1976, 1, 292-296
20. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies Nature 1997, 388, 839-840
21. Olanow, C. W.; Tatton, W. G. Etiology and pathogenesis of Parkinson's disease Annu. Rev. Neurosci. 1999, 22, 123-144
22. Xu, J.; Kao, S. Y.; Lee, F. J.; Song, W.; Jin, L. W.; Yankner, B. A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat. Med. 2002, 8, 600-606
23. Mosharov, E. V.; Larsen, K. E.; Kanter, E.; Phillips, K. A.; Wilson, K.; Schmitz, Y.; Krantz, D. E.; Kobayashi, K.; Edwards, R. H.; Sulzer, D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Neuron 2009, 62, 218-229
24. Park, S. S.; Schulz, E. M.; Lee, D. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein Eur. J. Neurosci. 2007, 26, 3104-3112
25. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
26. Moore, D. J.; West, A. B.; Dawson, V. L.; Dawson, T. M. Molecular pathophysiology of Parkinson's disease Annu. Rev. Neurosci. 2005, 28, 57-87
27. Mouradian, M. M. Recent advances in the genetics and pathogenesis of Parkinson disease Neurology 2002, 58, 179-185
28. Dutta, A. K.; Venkataraman, S. K.; Fei, X. S.; Kolhatkar, R.; Zhang, S.; Reith, M. E. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro- naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors Bioorg. Med. Chem. 2004, 12, 4361-4373
29. Biswas, S.; Hazeldine, S.; Ghosh, B.; Parrington, I.; Kuzhikandathil, E.; Reith, M. E.; Dutta, A. K. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphth alen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity J. Med. Chem. 2008, 51, 3005-3019
30. Biswas, S.; Zhang, S.; Fernandez, F.; Ghosh, B.; Zhen, J.; Kuzhikandathil, E.; Reith, M. E.; Dutta, A. K. Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}- 5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action J. Med. Chem. 2008, 51, 101-117
31. Ghosh, B.; Antonio, T.; Reith, M. E.; Dutta, A. K. Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl) piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease J. Med. Chem. 2010, 53, 2114-2125
32. Brown, D. A.; Mishra, M.; Zhang, S.; Biswas, S.; Parrington, I.; Antonio, T.; Reith, M. E.; Dutta, A. K. Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]- propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor Bioorg. Med. Chem. 2009, 17, 3923-3933
33. Ghosh, B.; Antonio, T.; Zhen, J.; Kharkar, P.; Reith, M. E.; Dutta, A. K. Development of (S)- N 6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)- N 6-propyl-4,5,6,7-tetrahydrobenzo[ d ]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models J. Med. Chem. 2010, 53, 1023-1037
34. Li, C.; Biswas, S.; Li, X.; Dutta, A. K.; Le, W. Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and lactacystin J. Neurosci. Res. 2010, 88, 2513-2523
35. Gogoi, S.; Antonio, T.; Rajagopalan, S.; Reith, M.; Andersen, J.; Dutta, A. K. Dopamine D2/D3 agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease ChemMedChem 2011, 6, 991-995
36. Matuszak, Z.; Reszka, K.; Chignell, C. F. Reaction of melatonin and related indoles with hydroxyl radicals: EPR and spin trapping investigations Free Radical Biol. Med. 1997, 23, 367-372
37. Shertzer, H. G.; Tabor, M. W.; Hogan, I. T.; Brown, S. J.; Sainsbury, M. Molecular modeling parameters predict antioxidant efficacy of 3-indolyl compounds Arch. Toxicol. 1996, 70, 830-834
38. De, S.; Adhikari, S.; Tilak-Jain, J.; Menon, V. P.; Devasagayam, T. P. Antioxidant activity of an aminothiazole compound: possible mechanisms Chem.-Biol. Interact. 2008, 173, 215-223
39. Grandy, D. K.; Marchionni, M. A.; Makam, H.; Stofko, R. E.; Alfano, M.; Frothingham, L.; Fischer, J. B.; Burke-Howie, K. J.; Bunzow, J. R.; Server, A. C. Cloning of the cDNA and gene for a human D2 dopamine receptor Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9762-9766
40. Girennavar, B.; Jayaprakasha, G. K.; Jadegoud, Y.; Nagana Gowda, G. A.; Patil, B. S. Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit Bioorg. Med. Chem. 2007, 15, 3684-3691
41. Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists Nature 1957, 180, 1200
42. Banala, A. K.; Levy, B. A.; Khatri, S. S.; Furman, C. A.; Roof, R. A.; Mishra, Y.; Griffin, S. A.; Sibley, D. R.; Luedtke, R. R.; Newman, A. H. N -(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl) arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity J. Med. Chem. 2011, 54, 3581-3594
43. Millan, M. J.; Di Cara, B.; Hill, M.; Jackson, M.; Joyce, J. N.; Brotchie, J.; McGuire, S.; Crossman, A.; Smith, L.; Jenner, P.; Gobert, A.; Peglion, J. L.; Brocco, M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole J. Pharmacol. Exp. Ther. 2004, 309, 921-935
44. McCall, R. B.; Lookingland, K. J.; Bedard, P. J.; Huff, R. M. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease J. Pharmacol. Exp. Ther. 2005, 314, 1248-1256